KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Notes Payables (2016 - 2024)

Emergent BioSolutions' Notes Payables history spans 8 years, with the latest figure at $800000.0 for Q3 2024.

  • For Q3 2024, Notes Payables fell 99.81% year-over-year to $800000.0; the TTM value through Sep 2024 reached $800000.0, down 99.81%, while the annual FY2023 figure was $413.7 million, 56.78% down from the prior year.
  • Notes Payables reached $800000.0 in Q3 2024 per EBS's latest filing, down from $415.2 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $957.3 million in Q4 2022 to a low of $800000.0 in Q3 2024.
  • Average Notes Payables over 5 years is $231.0 million, with a median of $31.6 million recorded in 2021.
  • Peak YoY movement for Notes Payables: skyrocketed 2929.43% in 2022, then plummeted 99.81% in 2024.
  • A 5-year view of Notes Payables shows it stood at $33.8 million in 2020, then decreased by 6.51% to $31.6 million in 2021, then surged by 2929.43% to $957.3 million in 2022, then tumbled by 56.78% to $413.7 million in 2023, then tumbled by 99.81% to $800000.0 in 2024.
  • Per Business Quant, the three most recent readings for EBS's Notes Payables are $800000.0 (Q3 2024), $415.2 million (Q2 2024), and $459.2 million (Q1 2024).